{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:24:44Z","timestamp":1795145084362,"version":"4.10.3"},"reference-count":30,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["90174-463338"],"award-info":[{"award-number":["90174-463338"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess clinical metrics and resource use of a 30-minute point-of-care test (POCT) for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) compared to laboratory-based testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Three English sexual health services (SHSs) were recruited as part of a study. Existing processes for CT\/NG testing and treatment were assessed, and adaptions to incorporate the CT\/NG POCT were developed during semi-structured interviews. Staff time and consumables data were collected by clinic staff prior to and following introduction of the POCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>SHSs selected patient groups for whom the CT\/NG POCT would be used. Testing and treatment process data were collected for 225 patients (n\u2009=\u2009118 POC; n\u2009=\u2009107 standard). The percentage of patients receiving unnecessary CT treatment was 5% (5\/95) and 13% (12\/93) for POC and standard care respectively. The average CT\/NG pathway cost varied and was on average \u00a361.55 for POC and \u00a350.88 for standard care. For the two SHSs where the POCT was used during a patient\u2019s visit, for standard and POC respectively, the average time to CT treatment was 10.0 and 0.0 days and to NG treatment, 0.3 and 0.0 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Use of a 30-minute POCT at three SHSs yielded clinical benefits by reducing time to treatment and unnecessary CT treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20499361211061645","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T07:27:07Z","timestamp":1638430027000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessing the clinical impact and resource use of a 30-minute chlamydia and gonorrhoea point-of-care test at three sexual health services"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-7441","authenticated-orcid":false,"given":"Susie","family":"Huntington","sequence":"first","affiliation":[{"name":"Aquarius Population Health Limited, Unit 29 Tileyard Studios, London N7 9AH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgie","family":"Weston","sequence":"additional","affiliation":[{"name":"Aquarius Population Health Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Adams","sequence":"additional","affiliation":[{"name":"Aquarius Population Health Limited, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"bibr1-20499361211061645","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.228486"},{"key":"bibr2-20499361211061645","unstructured":"BASHH Clinical Effectiveness Group. BASHH CEG 2015 summary guidance on tests for Sexually Transmitted Infections, 2015, https:\/\/www.bashhguidelines.org\/media\/1084\/sti-testing-tables-2015-dec-update-4.pdf (accessed December 2015)."},{"key":"bibr3-20499361211061645","unstructured":"Public Health England. Sexually transmitted infections and screening for chlamydia in England, 2017. Health Prot Rep 2018; 12, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/713962\/hpr2018_AA-STIs_v5.pdf"},{"key":"bibr4-20499361211061645","unstructured":"Public Health England. Audit report on turnaround times National Chlamydia Screening Programme, 2014, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/380604\/NCSP_audit_report_turnaround_times.pdf"},{"key":"bibr5-20499361211061645","doi-asserted-by":"crossref","first-page":"A37","DOI":"10.1136\/sextrans-2014-051561","volume":"91","author":"Harding-Esch E","year":"2015","journal-title":"Sex Transm Infect"},{"key":"bibr6-20499361211061645","unstructured":"British Association for Sexual Health and HIV (BASHH). Standards for the management of sexually transmitted infections (STIs) (Draft for public consultation), 2019, https:\/\/www.bashhguidelines.org\/media\/1210\/final-consultation-draft-of-standards-for-the-management-of-stis-180119.pdf"},{"key":"bibr7-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4386127"},{"key":"bibr8-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051997"},{"key":"bibr9-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1097\/POC.0b013e3181d2d8cc"},{"key":"bibr10-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2018.09.012"},{"key":"bibr11-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1177\/0956462417736431"},{"key":"bibr12-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2016-052988"},{"key":"bibr13-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051580"},{"key":"bibr14-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015447"},{"key":"bibr15-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000438"},{"key":"bibr16-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005322"},{"key":"bibr17-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-419"},{"key":"bibr18-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215380"},{"key":"bibr19-20499361211061645","unstructured":"Binx Health. Binx Health receives CE Mark for rapid chlamydia and gonorrhea test for mass markets. Multiplex test panel for Binx io\u00ae Point-of-Care platform. Positioned to radically reduce time to treatment, expand access to care, 2019, https:\/\/mybinxhealth.com\/news\/binx-health-receives-ce-mark-for-rapid-chlamydia-and-gonorrhea-test-for-mass-markets\/"},{"key":"bibr20-20499361211061645","volume-title":"Clinical performance data of Binx io CT\/NG POCT used for FDA approvals","author":"Binx Health","year":"2019"},{"key":"bibr21-20499361211061645","unstructured":"Curtis L, Burns A. Unit costs of health and social care 2018. Canterbury: Personal Social Services Research Unit, University of Kent, 2018, https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2018\/"},{"key":"bibr22-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2013-051147"},{"key":"bibr23-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.10.019"},{"key":"bibr24-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-020-5062-5"},{"key":"bibr25-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020394"},{"key":"bibr26-20499361211061645","unstructured":"Public Health England. Update on investigation of UK case of Neisseria gonorrhoeae with high-level resistance to azithromycin and resistance to ceftriaxone acquired abroad. Health Prot Rep 2018; 12: 1\u20134, https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/701185\/hpr1418_MDRGC.pdf"},{"key":"bibr27-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2009.08.003"},{"key":"bibr28-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2014-051941"},{"key":"bibr29-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-485"},{"key":"bibr30-20499361211061645","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006922"}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361211061645","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361211061645","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361211061645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:58:27Z","timestamp":1777593507000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361211061645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":30,"alternative-id":["10.1177\/20499361211061645"],"URL":"https:\/\/doi.org\/10.1177\/20499361211061645","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"20499361211061645"}}